Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review
Headache: The Journal of Head and Face Pain · 2025-02 · 65 (2) · 342-352
DOI: 10.1111/head.14903 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 17.01.2025. Verfasst von Marina Romozzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Migraine Disorders, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Antibodies targeting either the calcitonin gene–related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti‐CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect. However, differences in therapeutic targets, structure, and pharmacokinetic characteristics may influence their efficacy and safety differently. Therefore, in patients not achieving a clinically meaningful response with one anti‐CGRP antibody, switching to a different antibody may be a viable option. This review examines the pharmacological characteristics and distinctions among anti‐CGRP mAbs, highlighting their mechanisms of action and pharmacokinetic profiles, along with the clinical observational data of switching. Finally, we summarize suggestions from international guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
- Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.
- Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
- Headache and Neurosonology Unit, Fondazione Policlinico Campus Bio-Medico-Università Campus Bio-Medico Di Roma, Rome, Italy.
ORCID-Profile: Claudia Altamura, Bianca Raffaelli
Zitieren
APA
Romozzi, M., Munafò, A., Burgalassi, A., De Cesaris, F., Vigani, G., Altamura, C., Rivi, V., Guerzoni, S., Calabresi, P., Raffaelli, B., & Iannone, L. F. (2025). Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review. Headache: The Journal of Head and Face Pain, 65(2), 342-352. https://doi.org/10.1111/head.14903
Vancouver
Romozzi M, Munafò A, Burgalassi A, De Cesaris F, Vigani G, Altamura C, et al. Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review. Headache: The Journal of Head and Face Pain. 2025;65(2):342-352. doi:10.1111/head.14903
BibTeX
@article{Romozzi2025,
author = {Romozzi, Marina and Munafò, Antonio and Burgalassi, Andrea and De Cesaris, Francesco and Vigani, Giulia and Altamura, Claudia and Rivi, Veronica and Guerzoni, Simona and Calabresi, Paolo and Raffaelli, Bianca and Iannone, Luigi Francesco},
title = {Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
volume = {65},
number = {2},
pages = {342--352},
doi = {10.1111/head.14903}
}
EUVIMED